Insomnia is one of the most common sleep problems with an estimated prevalence of 10%-15% in the general population. Although adenosine A 2A receptor (A 2A R) agonists strongly induce sleep, their cardiovascular effects preclude their use in treating sleep disorders. Enhancing endogenous A 2A R signaling, however, may be an alternative strategy for treating insomnia, because adenosine levels in the brain accumulate during wakefulness. In the present study, we found that 3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)benzoic acid, denoted A 2A R positive allosteric modulator (PAM)-1, enhanced adenosine signaling at the A 2A R and induced slow wave sleep (SWS) without affecting body temperature in wild-type male mice after intraperitoneal administration, whereas the SWS-inducing effect of this benzoic acid derivative was abolished in A 2A R KO mice. In contrast to the A 2A R agonist CGS 21680, the A 2A R PAM-1 did not affect blood pressure or heart rate. These findings indicate that enhancing A 2A R signaling promotes SWS without cardiovascular effects. Therefore, small molecules that allosterically modulate A 2A Rs could help people with insomnia to fall asleep.
Introduction
Insomnia is one of the most common sleep problems with an estimated prevalence of 10%-15% in the general population and 30%-60% in the older population (Roth, 2007) . Moreover, insomnia frequently neurotransmitter γ-aminobutyric acid (Wafford and Ebert, 2008) . These medications, however, are plagued by a wide range of adverse effects, including muscle relaxation, rebound insomnia, changes in appetite, next-day sedation, cognitive impairment, amnesic effects, and development of drug tolerance and dependence (Aragona, 2000; Vgontzas et al., 1995) . Orexin receptor antagonists were also recently developed and approved for treating insomnia (Cox et al., 2010) . The major issues of these drugs are next-morning sleepiness with possible muscle weakness, strange dreams, sleep-walking, and other nighttime behaviors or suicidal ideation (Jacobson et al., 2014) . Moreover, because orexin receptor antagonists mostly work by preventing arousal from sleep, they are generally ineffectual in people who have problems falling asleep. A highly selective adenosine A 2A receptor (A 2A R) agonist, CGS 21680, produces profound increases in sleep after infusion into the subarachnoid space underlying the ventral surface region of the rostral basal forebrain in rats, the lateral ventricle of mice, or the lateral preoptic area of rats (Satoh et al., 1999; Scammell et al., 2001; Urade et al., 2003; Methippara et al., 2005) . Administration of an A 2A R agonist is not considered to have clinical potential for the treatment of sleep disorders, however, due to its adverse cardiovascular effects, which include hypotension and tachycardia (de Lera Ruiz et al., 2014) . A positive allosteric modulator (PAM) may evoke selective physiologic A 2A R responses because, in contrast to an A 2A R agonist, its actions are limited to when and where adenosine is released. Adenosine levels in the brain progressively increase during wakefulness (Porkka-Heiskanen et al., 1997) , and therefore allosteric modulation of A 2A Rs to promote the somnogenic effects of the increased adenosine may be an alternative strategy for treating insomnia.
In the present study, we identified a small lipophilic monocarboxylate (3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)benzoic acid), denoted A 2A R PAM-1, that induces slow-wave sleep (SWS), the major part of sleep characterized by slow and high-voltage brain waves, by enhancing A 2A R signaling without affecting body temperature, blood pressure, or heart function in mice.
Material and methods

Reagents
Adenosine (Nacalai Tesque, Kyoto, Japan), CGS 21680 (SigmaAldrich, St. Louis, MO), Cremophor ® EL (Sigma-Aldrich), DMSO (Nacalai Tesque), DMEM (Nacalai Tesque), FBS (Nichirei Biosciences, Tokyo, Japan), HBSS (Gibco, Waltham, MA), hygromycin B (Wako, Tokyo, Japan), ketamine hydrochloride (Ketalar, Daiichi Sankyo, Tokyo, Japan), nonessential amino acids (NEAA; Nacalai Tesque), penicillin/streptomycin (Wako), pentobarbital (Somnopentyl, Kyoritsu Seiyaku, Tokyo, Japan), puromycin (InvivoGen, San Diego, CA), saline (Otsuka, Tokyo, Japan), xylazine hydrochloride (Celactal, Bayer, Tokyo, Japan), ZM241385 (Tocris Bioscience, Bristol, UK), 3-isobutyl-1-methylxanthine (IBMX; Tocris Bioscience) and HEPES (Gibco).
Animals
Male mouse lines on a C57BL/6 background, including wild-type and A 2A R KO (Chen et al., 1999) mice, which were maintained at the International Institute for Integrative Sleep Medicine and weighing 21-27 g (10-15 weeks old), were used in the experiments. The animals were housed in an insulated and soundproof recording chamber that was maintained at an ambient temperature of 23 ± 0.5°C with a relative humidity of 50 ± 5% and an automatically controlled 12 h light/12 h dark cycle (light on at 8:00, illumination intensity ≈ 100 lux). All animals had free access to food and water. This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the US National Institutes of Health (National Research Council, 2011). Experimental protocols were in compliance with relevant Japanese and institutional laws and guidelines and approved by the University of Tsukuba animal ethics committee (protocol #14-322). Every effort was made to minimize the number of animals used as well as any pain and discomfort experienced by the animals.
Mouse A 2A R-expressing Chinese hamster ovary cells
The flag epitope-tagged open reading frame of A 2A R was amplified by PCR from mouse brain total RNA. The resultant amplicon was cloned into a pMXs-IRES-Puro retroviral vector (Kitamura et al., 2003) . The plasmid was then transfected into the retrovirus packaging cell line Plat-E (Morita et al., 2000) . The supernatant of transfected Plat-E cells was recovered after 24 h and applied to Chinese hamster ovary (CHO) cells strongly expressing the ecotropic receptor for the retrovirus (Montminy et al., 1990) . Mouse A 2A R-expressing CHO (mA 2A R-CHO) cells were selected in DMEM supplemented with 5% FBS and 1% NEAA by treatment with hygromycin B (250 μg ml ) and puromycin (10 μg ml
−1
). The mA 2A R-CHO cells were subsequently maintained in DMEM supplemented with 5% FBS, 1% NEAA, 1% penicillin/streptomycin, and 250 μg ml −1 hygromycin B at 37°C in an atmosphere of 5% CO 2 .
cAMP assay
Activation of A 2A Rs was quantified by cyclic adenosine monophosphate (cAMP) accumulation in CHO cells expressing mouse A 2A Rs. CHO cells were suspended in HBSS containing 1 M HEPES and 0.25 M IBMX in 384-well micro-plates (2 × 10 3 cells/well), and incubated with adenosine and A 2A R PAM-1 at the indicated concentrations for 30 min at 25°C. The detection mixture containing the Eu-cAMP tracer and ULight-anti-cAMP antibody was added and incubated for 1 h at 25°C. A micro-plate reader (ARVO X5, Perkin Elmer, Waltham, MA; excitation: 340 nm; emission: 665 nm) was used to measure the Förster resonance energy transfer (FRET) signal. All experiments were performed according to the manufacturer's instructions (LANCE Ultra cAMP Kit, PerkinElmer). The cAMP levels are based on the dynamic range ("linear portion") of the cAMP standard curve and normalized to the baseline or adenosine treated group.
Stereotaxic surgery for the placement of EEG/EMG electrodes
Mice were anesthetized with pentobarbital [50 mg kg −1 body weight, intraperitoneal (i.p.)] and then placed in a stereotaxic apparatus. Electroencephalogram (EEG) and electromyogram (EMG) electrodes for polysomnographic recordings were chronically implanted in the mice (Oishi et al., 2016) . The implant comprised two stainless steel screws (1 mm in diameter) inserted through the skull above the cortex (anteroposterior, +1.0 mm; left-right, −1.5 mm from bregma or lambda) according to the atlas of Paxinos and Franklin (2004) that served as the EEG electrodes. Two insulated, stainless steel Tefloncoated wires were placed bilaterally into both trapezius muscles and served as the EMG electrodes. All electrodes were attached to a micro connector and fixed to the skull with dental cement.
Pharmacologic treatment and infusion cannula implantation
For control data, mice were injected with saline or vehicle (10 ml kg For intracerebroventricular (i.c.v.) infusion of A 2A R PAM-1, a stainless-steel cannula was inserted into the mouse brain during surgery 0.5 mm anterior and 1.6 mm lateral to bregma to a depth of 1.6 mm below the dura at an angle of 20°, thus placing the cannula into the lateral ventricle. To ensure correct placement of cannula, a plastic tube filled with saline was attached to the infusion cannula; a drop in the meniscus indicated that the cannula tip was in the ventricle. During the experiments, the mice were infused continuously using an infusion pump with artificial cerebrospinal fluid into the lateral ventricle of the brain at a speed of 1 μl h −1
. Sleep-wakefulness states were monitored for a period of 36 h after infusion of each compound. Saline infusion recordings were obtained in each animal for 36 h, beginning at 20:00, which served as the control for the same animal. In the next experiment, A 2A R PAM-1 (200 nmol h −1 ) was infused into the lateral ventricle of the mouse brain for 12 h (20:00 to 8:00).
Vigilance state assessment based on EEG/EMG polygraphic recordings
Ten days after surgery, the mice were individually housed in transparent barrels in an insulated soundproof recording chamber and connected to the EEG-EMG recording cables for 3-5 days of habituation before starting the polygraphic recordings. To evaluate the spontaneous sleep-wake cycle, each animal was recorded for 24 h beginning at 20:00, the onset of the dark period. The animals then entered the pharmacologic phase of the study in which sleep-wakefulness parameters were recorded for 36 h. The data collected during the first 24 h also served as baseline comparison data for the second experimental day. Cortical EEG and EMG signals were amplified, filtered , and digitized at a sampling rate of 128 Hz, and then recorded using data acquisition software SleepSign ® (Kissei Comtec, Matsumoto, Japan). The vigilance states were classified offline in 10-s epochs into three stages, i.e., wakefulness, rapid eye movement (REM) sleep, and SWS by SleepSign ® (ver 3.4) according to standard criteria (Oishi et al., 2016) . As a final step, defined vigilance stages were examined visually, and corrected when necessary.
Blood pressure and heart rate measurement
The blood pressure of the mice was measured using the tail-cuff method with a BP-98A blood pressure device (Softron, Tokyo, Japan). The same time period (13:00-16:00) was selected for testing the blood pressure of each mouse (9-12 weeks old) to avoid normal daily variations in blood pressure. Five consecutive days were used to habituate the mice to the device. To optimize cardiovascular circulation, mice were wrapped in a cotton sheet and, except for the tail, maintained at 37°C within a cylinder heater. A programmable sensor with an inflatable balloon attached to a tail cuff was used to monitor tail pulse waves and measure blood pressure when the pulse waves were stable and rhythmic. Blood pressure measurement was read and recorded by the software. After five consecutive training days, mice were randomly assigned to one of three groups and injected with saline (10 ml kg
Blood pressure was measured at 30 min, 1 h 30 min, and 2 h 30 min after injection (at each time-point, 20 readings for each mouse were collected). After testing, the mice were gently picked up by the tail and returned to their cages. The heart rate of the mice was measured by telemetry. Mice were anesthetized with ketamine hydrochloride (80 mg kg −1 , i.p.) and xylazine hydrochloride (8 mg kg , i.p.) and a PhysioTel F20-ETA mouse telemetry transmitter (Data Science International, St. Paul, MN) was placed in the midline of the mouse back and fixed with surgical sutures. The negative (white) electrode was placed in the trapezius muscle, while the positive (red) electrode was sutured to a muscle in the back opposite the xiphoid process. Each mouse was singly housed in a cage after surgery with a distance of at least 1 m between cages to avoid interference between telemetry transmitters. After 7 days of recovery, the mice were randomly assigned to one of three groups and injected with saline (10 ml kg
.). The transmitted cardiovascular signal was
analyzed for 2 h after the injections using Data Science International software.
Heart rhythm measurement
The cardiac rhythm of mice was measured by electrocardiography (ECG). Mice were anesthetized with ketamine hydrochloride (80 mg kg , i.p.) and fixed with needles on a styrofoam platform. Mice were then gently pushed into a position where the two front paws and the left rear paw are in contact with 25-gauge needles that served as ECG electrodes. For intracardiac electrography, the throat of the mice was opened and the internal jugular vein was isolated to insert a catheter along the course of the vein to the right atrium. Electrographic signals were 5.000-10.000-fold amplified and filtered (0.5-250 Hz) with an AC-601G system (Nihon Kohden, Tokyo, Japan). The same time period (10:00-12:00) was selected for testing the heart rhythm to avoid normal daily variations in the cardiac rhythm. Mice were randomly assigned to groups that received A 2A R PAM-1 (75 mg kg , i.p.) injections. After recording the baseline for 1-2 min, mice were injected with drugs and recording continued for 30 min. The data were analyzed using LabChart Pro software (ADInstruments, Dunedin, New Zealand).
Body temperature measurement
The core body temperature of the mice was measured using Thermochron iButtons (KN Laboratories, Osaka, Japan). iButtons were programmed to monitor core body temperature every 5 min for 14 consecutive days beginning at the end of the recovery period. The mice were anesthetized with pentobarbital (50 mg·kg -1 , i.p.). The skin of the abdomen was shaved and cleaned with 70% ethanol and a longitudinal, 2-cm incision was made along the midline. One iButton cleaned with 70% ethanol was placed in the peritoneal cavity and the incision was closed with nylon sutures. The mice were housed individually in cages after surgery and experiments were conducted after a 10-day recovery period. iButtons were removed from the animals after cervical dislocation under anesthesia and RhManager software (KN Laboratories) was used to collect the recorded data from the iButtons.
Synthesis of A 2A R PAM-1
A solution of 2,3,4-fluorobenzoic acid (1.35 g, 7.68 mmol), 2-fluoro-4-iodoaniline (1.91 g, 8.06 mmol), and lithium amide (0.702 g, 30.6 mmol) in tetrahydrofuran (10.5 ml) was reacted using a standard method (Cai et al., 2008) water and filtered. The filtrate was freeze-dried to obtain the sodium salt of A 2A R PAM-1 (0.265 g, 89%) as a gray solid (m.p. 290-291°C; Anal. Calcd for C 13 H 6 NO 2 ·Na·1.5H 2 O: C, 35.32; H, 2.05; N, 3.17. Measured: C, 35.34; H, 1.91; N, 3.14) . The sodium salt of A 2A R PAM-1 was used for all in-vivo experiments.
Statistical analysis
Statistical analyses were carried out using SigmaPlot (Systat Software, San Jose, CA). All results are presented as mean ± standard error of the mean (SEM). Two-tailed Student's t-tests were used for statistical comparisons between two groups (Fig. 1A, B, D, E, Fig. 2C, D,  F, Fig. 3B, D, Fig. 4B , Fig. 5A and B, Fig. S2A, B, Fig. S4B, Fig. S5A -C, and Fig. S6A-C) . For t-tests, the normality of each dataset was established using the Kolmogorov-Smirnov test. Two-way repeated-measures analysis of variance (ANOVA) followed by the Tukey test were used for dose-response effects on the amounts of the SWS, REM sleep, and wakefulness (Figs. 2B and 3A, C, Fig. 4A, Fig. S3A and Fig. S5A ) (Chrivia et al., 1993) . In all of the cases, P < 0.05 was considered significant (significance levels are indicated in figures as *: P < 0.05, **: P < 0.01 or ***: P < 0.001). 
Results
Screening of small-molecule compounds for allosteric A 2A R modulation
We established CHO cells that express mouse A 2A Rs ( Figure S2 ) using a retrovirus-mediated gene transfer method (Kitamura et al., 2003) . We used these mA 2A R-CHO cells to screen 1173 small-molecule compounds for their allosteric effects at A 2A Rs. The compounds were synthesized in Dr. Hiroshi Nagase's laboratory at the University of Tsukuba. A 2A R activity in CHO cells was determined by measuring cAMP produced after adding adenosine and small-molecule compounds using a fluorescence resonance energy transfer immunoassay. Because a one-compound-one-well approach may be wasteful research conduct due to a likely small number of active compounds in our library, we tested initially 391 mixtures containing three compounds each in triplicates. We selected mixtures that significantly enhanced the effects of adenosine at the A 2A Rs (P < 0.01, unpaired t-test) for individual compound testing and found that eight of the mixtures showed an effect according to this criterion (Mixture 124: t (4) = 27.9, P < 0.0001, Mixture 181: t (4) = 31.5, P < 0.0001, Mixture 194: t (4) = 30.9, P < 0.0001, Mixture 211: t (4) = 9.6, P = 0.0006, Mixture 274: t (4) = 11, P = 0.0003, Mixture 319: t (4) = 6.81, P = 0.0024, Mixture 332: t (4) = 8.62, P = 0.0009, Mixture 346: t (4) = 4.71 P = 0.0091, unpaired t-test; Fig. 1A ). Further individual testing of compounds in the eight mixtures revealed that only compound 371 (3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)benzoic acid) in mixture 124 enhanced adenosine-induced A 2A R activation (t (4) = 9.14, P = 0.0007, unpaired t-test; Fig. 1B) . A cell culture bioassay revealed that cAMP levels were not altered by treating A 2A R-expressing or native CHO cells with compound 371 in the absence of adenosine or by treating native CHO with adenosine and compound 371 (Fig. 1C) , suggesting that compound 371 is likely a positive allosteric modulator for A 2A Rs, and we therefore named this compound A 2A R PAM-1. Co-treatment of A 2A R-expressing CHO cells with 150 nM adenosine and various concentrations of A 2A R PAM-1 (i.e., 25, 50, and 100 μM) amplified adenosine A 2A R-evoked cAMP accumulation in a dose-dependent manner by 42% ± 1.4%, 46% ± 1.1%, and 50% ± 1.0%, respectively (25 μM A 2A R PAM-1: t (4) = 4.47, P = 0.011, 50 μM A 2A R PAM-1: t (4) = 7.21, P = 0.0019, 50 μM A 2A R PAM-1 vs. 25 μM A 2A R PAM-1: t (4) = 4.71, P = 0.0092, 100 μM A 2A R PAM-1: t (4) = 9 P = 0.0008, 100 μM A 2A R PAM-1 vs. 25 μM A 2A R PAM-1: t (4) = 8.08, P = 0.0012, 100 μM A 2A R PAM-1 vs. 50 μM A 2A R PAM-1: t (4) = 3.65, P = 0.021, unpaired t-test; Fig. 1D ). Similarly, co-treatment of A 2A R-expressing CHO cells with 100 μM A 2A R PAM-1 and 50, 100, or 150 nM adenosine increased A 2A R activity in the CHO cells in a dose-dependent manner by 55% ± 0.4%, 66% ± 1.5%, and 72% ± 1.7%, whereas 100 μM A 2A R PAM-1 did not significantly enhance the cellular activity of A 2A R-expressing CHO cells treated with 250 nM adenosine (50 nM Adenosine: t (4) = 14.9, P = 0.0001, 50 nM Adenosine vs. 100 nM Adenosine: t (4) = 7.04, P = 0.0021, 50 nM Adenosine vs. 150 nM Adenosine: t (3) = 12.40, P = 0.0011, 50 nM Adenosine vs. 250 nM Adenosine: t (4) = 11.79, P = 0.00029, 100 nM Adenosine: t (4) = 6.18, P = 0.034, 150 nM Adenosine: t (3) = 4.98, P = 0.015, unpaired t-test; Fig. 1E ).
Intraperitoneal administration of A 2A R PAM-1 induces SWS without affecting body temperature in mice
We then tested the effect of intraperitoneal administration of A 2A R PAM-1 on the sleep/wake behavior of wild-type mice. We analyzed EEG and EMG recordings made after saline or A 2A R PAM-1 injections during the dark period at 22:00, when mice usually spend most of their time awake. Although baseline sleep and wake of mice 24 h prior to treatment was not significantly different between the saline and A 2A R PAM-1 groups during the dark period ( Figure S3 t (6) = 5.45, P = 0.0015, unpaired t-test; Fig. 2A , B, D). The total amount of SWS was increased by 60.8 ± 11.4 min for 8 h with the highest dose of A 2A R PAM-1 (i.e., 75 mg kg
) compared with saline treatment, whereas wakefulness was decreased by 59.2 ± 12.8 min (SWS: t (7) = 4.27, P = 0.0036, Wake: t (7) = 4.33, P = 0.0034, unpaired t-test; Figure S4A ). On the other hand, wake episode numbers lasting 120-239 s increased by 307% (t (7) = 3.88, P = 0.006, unpaired t-test), and wake episode numbers lasting 480-959 s and 960-1909 s decreased by 47% (t (7) = 2.89, P = 0.02, unpaired t-test) and 88% (t (7) = 4.60, P = 0.002, unpaired t-test), respectively, compared with the saline injection. The mean duration of wake episodes decreased by 38% (t (7) = 3.38, P = 0.01, unpaired t-test) compared with saline, but the duration of the SWS and REM sleep episodes was not significantly different after A 2A R PAM-1 (75 mg kg , i.p.) also did not significantly affect the number of transitions between SWS, wake, and REM sleep ( Figure S4C ).
To assess whether EEG activity was altered by A 2A R PAM-1 administration, we compared the normalized EEG power spectrum of SWS in mice treated with saline or A 2A R PAM-1 (Fig. 2E) . EEG activity in the frequency range of 0.5-25 Hz during SWS was indistinguishable between A 2A R PAM-1-induced and natural (saline injection) SWS. These data suggest that A 2A R PAM-1 induced physiologic sleep rather than abnormal sleep.
We also measured the effect of intraperitoneal administration of 75 mg kg −1 A 2A R PAM-1 or 1 mg kg −1 of the A 2A R agonist CGS 21680
(as positive control) on the body temperature of the mice during the dark period (Fig. 2F) . Although CGS 21680 strongly decreased the body temperature for almost 2 h (t (10) = 3.68, P = 0.0042 at 22:15, t (10) = 10.48, P < 0.0001 at 23:15, t (10) = 2.33, P = 0.041 at 00:05 vs. saline injected group, unpaired t-test), A 2A R PAM-1 did not affect the body temperature of the mice. These data suggest that A 2A R PAM-1 induces physiologic sleep independent of the body temperature.
Sleep-inducing effect of A 2A R PAM-1 was suppressed by blocking A 2A Rs
We further investigated whether A 2A Rs mediate the sleep-inducing , i.p.) or vehicle 30 min before the A 2A R PAM-1 injection at 22:00. The dose of ZM241385 was selected based on previous studies (El Yacoubi et al., 2000; Nakamura et al., 2016) . In the presence of ZM241385, A 2A R PAM-1 injection produced no significant changes in SWS (Fig. 3A) , indicating that ZM241385 completely blocked the A 2A R PAM-1-induced SWS. When we calculated the total amount of SWS for 4 h after the intraperitoneal injection of A 2A R PAM-1 (Fig. 3B) , we found that it did not significantly alter the total amount of SWS after ZM241385 pretreatment. ZM241385 pretreatment alone also had no significant effect on SWS compared with vehicle pretreatment (Vehicle + Saline vs. Vehicle +75 mg kg t (8) = 6.10, P = 0.00028, unpaired t-test; Fig. 3B ). We then administered 75 mg kg −1 A 2A R PAM-1 (i.p.) into A 2A R KO mice and their wild-type littermates at 22:00. We observed no significant changes in SWS in the A 2A R KO mice compared with saline treatment, whereas SWS was increased by 74.3 ± 12.0 min for 6 h in wild-type littermates of A 2A R KO mice (F (1,190) = 20.83, P = 0.003, two way repeated measures ANOVA-Tukey test, t (14) = 5.63, P < 0.0001, unpaired t-test; Fig. 3C and D) . Concomitantly, wakefulness was decreased in the wild-type littermates of A 2A R KO mice (F (1,190)= 16.14, P = 0.005, two way repeated measures ANOVA-Tukey test, t (14) = 5.50, P < 0.0001, unpaired t-test), whereas neither REM sleep in these mice nor wakefulness and REM sleep in the KO mice were affected by intraperitoneal administration of 75 mg kg −1 A 2A R PAM-1 ( Figure S5 ). Baseline sleep and wake of the KO mice and their wild-type littermates 24 h prior to treatment was not different between the saline and A 2A R PAM-1 groups during the dark period (data not shown). These findings suggest that A 2A R are necessary for A 2A R PAM-1 to induce SWS.
Intracerebroventricular administration of A 2A R PAM-1 induces SWS in mice
To elucidate whether the sleep-inducing effect of A 2A R PAM-1 is mediated via A 2A Rs expressed in the brain, we infused A 2A R PAM-1 into the lateral ventricle of wild-type mice at 200 nmol h −1 during the dark period (20:00 to 8:00) and assessed EEG and EMG activity. Infusion with A 2A R PAM-1 for 12 h increased the time spent in SWS 5 h after the infusion, resulting in a total SWS increase during the dark period of 141.6 ± 12.5 min compared with saline infusion (F (1,118) = 34.40, P = 0.004, two way repeated measures ANOVA-Tukey test, t (8) = 5.67, P=0.00047, unpaired t-test; Fig. 4A and B) . Concomitantly, total wakefulness was decreased by 145. ) into mice affected SWS and wake episode numbers during the dark period ( Figure S6A ). SWS episode numbers lasting 0-29 s, 30-59 s, and 60-120 s increased by 267% (t (8) = 7.56, P < 0.0001, unpaired t-test), 196% (t (8) = 3.47, P = 0.008, unpaired t-test), and 154% (t (8) = 2.88, P = 0.02, unpaired t-test), respectively, and wake episode numbers lasting 0-29 s, 30-59 s, and 60-120 s also increased by 205% (t (8) = 3.97, P = 0.004, unpaired t-test), 177% (t (8) = 3.55, P = 0.007, unpaired t-test), and 137% (t (8) , i.c.v.) increased the number of transitions between SWS and wakefulness by 148% (t (8) = 4.91, P = 0.001, unpaired t-test), and from wakefulness to SWS by 128% (t (8) = 4.26, P = 0.002, unpaired ttest) compared with the saline-infused group ( Figure S6C) .
Moreover, the EEG activity in the frequency range of 0.5-25 Hz during SWS episodes was indistinguishable between mice treated with saline or A 2A R PAM-1 (Fig. 4C ). These data suggest that A 2A R PAM-1 induces physiologic sleep rather than abnormal sleep via A 2A Rs that are likely expressed in the brain.
3.5. Intraperitoneal administration of A 2A R PAM-1 does not affect blood pressure or heart rate A 2A R agonists evoke cardiovascular effects (Hutchison et al., 1989; Kirkup et al., 1998; Nekooeian and Tabrizchi, 1996) . We therefore tested the effect of intraperitoneal administration of A 2A R PAM-1 on blood pressure and heart rate in wild-type mice. First, we measured blood pressure in mice 30, 90, and 150 min after intraperitoneal injection of 75 mg kg −1 A 2A R PAM-1 or 1 mg kg −1 of the A 2A R agonist CGS 21680 using an electrosphygmomanometer (Fig. 5A ). The dose of the A 2A R agonist CGS 21680 was selected based on previous studies in mice (Carvalho et al., 2017; Nakav et al., 2008; Ohta and Sitkovsky, 2001) . Compared with saline treatment, the systolic, and diastolic blood pressures were significantly decreased for up to 90 min after injecting the A 2A R agonist CGS 21680 (SBP at 30 min: t (9) = 10.55, P < 0.0001, SBP at 90 min: t (9) = 7.51, P < 0.0001, DBP at 30 min: t (9) = 6.60, P < 0.0001, DBP at 90 min: t (9) = 5.86, P < 0.0001, unpaired t-test) and returned to normal levels within 150 min after the injection. In contrast, blood pressure was not changed after intraperitoneal administration of A 2A R PAM-1 (75 mg kg −1 ) at 30, 90, or 150 min after treatment. In addition, we measured the heart rate of mice after intraperitoneal injection of 75 mg kg −1 A 2A R PAM-1 or 1 mg kg −1 A 2A R agonist CGS 21680 using the telemetry implants (Fig. 5B) . The heart rate of the mice increased after intraperitoneal administration of the A 2A R agonist CGS 21680 (HR at 60 min: t (8) = 2.34, P = 0.047, HR at 75 min: t (8) = 2.90, P = 0.019, HR at 90 min: t (8) = 2.80, P = 0.023, unpaired t-test), whereas the heart rate was not affected by injection of 75 mg kg −1 A 2A R PAM-1. Finally, we monitored the heart rhythm in anesthetized mice after intraperitoneal administration of 75 mg kg −1 of A 2A R PAM-1 or 1 mg kg −1 of A 2A R agonist CGS 21680 using intracardiac EGM. We observed sinus arrhythmia in mice after intraperitoneal administration of A 2A R agonist CGS 21680, whereas injection of 75 mg kg −1 A 2A R PAM-1 did not cause abnormalities of the cardiac rhythm (Fig. 5C ).
Discussion
Our observations suggest that enhancing A 2A R signaling by intraperitoneal administration of A 2A R PAM-1 induces SWS without cardiovascular effects in mice. Therefore, A 2A R-modulating compounds may provide safe options for the treatment of insomnia and poorquality sleep.
Over the past century, several putative hypnogenic substances implicated in the sleep homeostatic process have been identified, including prostaglandin D 2 (Qu et al., 2006) , cytokines (Krueger et al., 1984) , anandamide (García-García et al., 2009 ), urotensin II peptide (Huitron-Resendiz et al., 2005 , and adenosine (Porkka-Heiskanen et al., 1997) . Adenosine represents a state of relative energy deficiency: ATP depletion positively correlates with an increase in extracellular adenosine levels (Kalinchuk et al., 2003) and positively associates with sleep (Porkka-Heiskanen et al., 1997) . Adenosine levels in samples collected from several brain areas of cats during spontaneous sleepwake cycles by in vivo microdialysis were higher during SWS than during wakefulness for all probed brain areas (Porkka-Heiskanen et al., 1997) . The observation in animals that adenosine levels are elevated during prolonged wakefulness may explain why an allosteric modulator could effectively enhance the sleep-inducing effect of endogenous adenosine in the brain. On the other hand, adenosine is absent or its concentration is too low in the cardiovascular system under physiologic conditions to affect blood pressure and heart function after administration of an allosteric modulator of A 2A R.
Medicinal chemistry for A 2A Rs has been widely developed in recent decades for use in myocardial perfusion imaging and the treatment of inflammation and neuropathic pain (de Lera Ruiz et al., 2014) . Several A 2A R agonists that entered clinical trials elicited undesirable side effects, however, thus precluding their further development. On the other hand, allosteric modulators bind at a distinct site other than the natural ligand binding site (i.e., the orthosteric site) and exert their effects only in the presence of the orthosteric ligand (Wenthur et al., 2014) . As a consequence, an allosteric modulator mimics the activity duration of the natural ligand and thus the pharmacologic response of an allosteric modulator more closely resembles the natural physiologic activity of the receptor than is possible with a synthetic agonist. Because efforts to evoke pharmacologic A 2A R responses have focused almost exclusively on the use of orthosteric ligands, however, the possibility that A 2A R responses, especially in the brain, can be fine-tuned using allosteric modulators has received very little attention (Göblyös and Ijzerman, 2009) .
Moreover, it is widely accepted that the basic adenosine scaffold must be maintained in an A 2A R agonist (Fredholm et al., 2011) . Thus, the development of adenosine analogs for treating the central nervous system, including sleep induction for treating insomnia, is restricted by the poor transport of these drugs through the brain endothelial cells, which are connected by tight junctions to establish a blood-brain barrier (BBB) (Pardridge et al., 1994) . In contrast, A 2A R PAM-1, when administered intraperitoneally, exhibits a sleep-inducing effect that is likely mediated by A 2A Rs in the brain and thus appears to cross the BBB. Small lipophilic monocarboxylates like A 2A R PAM-1 likely pass through the BBB by passive diffusion or via a monocarboxylate transport system (Tsuji, 2005) . Therefore, allosteric modulation of A 2A Rs has the potential to cause pharmacologic effects in the central nervous system after systemic administration, resulting in good quality sleep.
Our study did not investigate how and where the A 2A R PAM-1 binds at the receptor to exert its allosteric effect. Therefore, an important next step will be to examine the allosteric interactions of A 2A R PAM-1 and the receptor using binding assays and crystal structure analysis. With respect to the latter, a crystal structure of the human A 2A R bound to a bitopic antagonist revealed a potential allosteric pocket (Sun et al., 2017) and another study suggested that a sodium ion binding site can be exploited for allosteric modulation of A 2A R (Gutiérrez-de-Terán et al., 2013) . Moreover, to solidify the sleep enhancing effect of the A 2A R PAM-1, it may be necessary to test the A 2A R PAM-1 in mice at the time of normal sleep onset, i.e., A 2A R PAM-1 administration at the onset of the light period, or in an animal model of insomnia, for example, a mouse model mimicking the human first-night effect (Xu et al., 2014) .
Due to work schedules and expectations, lifestyle choices, pre-existing medical conditions, or aging, people are coping with an increasingly wide range of sleep problems, including difficulties with falling and staying asleep, waking up too early, and poor-quality ("nonrestorative") sleep. Deficiencies in sleep cause significant social losses due to increased prevalence of mood disorders, lead to decreased economic productivity, and are linked to traffic and work-related accidents due to excessive daytime sleepiness (Groeger et al., 2004; Saddichha, 2010; Sutton et al., 2001 ). Insufficient sleep is not only by itself a major problem in modern society, but is also an established risk factor for obesity, diabetes, heart disease, and other lifestyle diseases (Colten and Altevogt, 2006) . Moreover, psychiatric illnesses, especially anxiety and mood disorders, are long recognized to be a frequent cause of insomnia (Okuji et al., 2002) .
Conclusions
The findings of our study indicate that enhancing A 2A R signaling promotes SWS without cardiovascular effects. Therefore, small molecules that allosterically modulate A 2A Rs could help people with sleep problems to fall asleep and thus also be a potential treatment for psychiatric disorders.
Our study was conducted in mice, the most commonly used model organism of human disease. Results in mice, however, are not particularly reliable for predicting human study outcomes, mostly due to the limited genetic diversity associated with common laboratory mice. Therefore, many obstacles remain to be overcome in generating a novel drug for the treatment of insomnia in humans.
